# United States SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

CCI	TTT.	'T	TIT	$\mathbf{T}^{r}$	12	
SC:	пс	IJ	UL	æ	TO	U

Under the Securities Exchange Act of 1934 (Amendment No. 6)\*

# MYOVANT SCIENCES LTD.

(Name of Issuer)

Common Shares (Title of Class of Securities)

G637AM102 (CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

⊠ Rule 13d-1(c)
□ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

# CUSIP No. G637AM102

<ol> <li>Names of Reporting Persons         BB Biotech AG         Check the Appropriate Box if a Member of a Group (See Instructions)         (a) ☑ (b) □         </li> <li>SEC Use Only</li> <li>Citizenship or Place of Organization</li> <li>Switzerland</li> </ol>						
<ol> <li>Check the Appropriate Box if a Member of a Group (See Instructions)         <ul> <li>(a) ☑ (b) □</li> </ul> </li> <li>SEC Use Only</li> <li>Citizenship or Place of Organization</li> </ol>	Names of Reporting Persons					
<ol> <li>Check the Appropriate Box if a Member of a Group (See Instructions)         <ul> <li>(a) ☑ (b) □</li> </ul> </li> <li>SEC Use Only</li> <li>Citizenship or Place of Organization</li> </ol>						
(a) ⊠ (b) □  3. SEC Use Only  4. Citizenship or Place of Organization						
SEC Use Only      Citizenship or Place of Organization						
4. Citizenship or Place of Organization						
4. Citizenship or Place of Organization						
State and and	Citizenship or Place of Organization					
5. Sole Voting Power						
Number of 0						
Shares 6. Shared Voting Power						
Beneficially						
Owned by 6,122,039						
Each 7. Sole Dispositive Power						
Reporting						
Person 0						
with: 8. Shared Dispositive Power						
6,122,039						
9. Aggregate Amount Beneficially Owned by Each Reporting Person						
7. Aggregate Amount Beneficiany Owned by Each Reporting Ferson	Aggregate Amount Beneficially Owned by Each Reporting Person					
6,122,039						
Check if the Aggregate Amount in Row (9) Excludes Certain Shares						
Percent of Class Represented by amount in Row (9)						
6.6%						
Type of Reporting Person (See Instructions)						
HC. CO						

## CUSIP No. <u>G637AM102</u>

1.	Names of Reporting Persons					
	Biotech Target N.V.					
	IDC	r.a	"Control Name of the control of the control of NAME of the control			
			ification Nos. of above persons (entities only): N/A			
2.	Check	the A	Appropriate Box if a Member of a Group (See Instructions)			
	(-) V		45 E			
	(a) ⊠		(b)			
3.	SEC U	se O	nly			
4.	Citizenship or Place of Organization					
	Curacao					
		5.	Sole Voting Power			
Nui	Number of 0					
	hares	6.	Shared Voting Power			
	eficially					
	ned by		6,122,039			
	Each 7. Sole Dispositive Power		Sole Dispositive Power			
	Reporting Person 0					
			Shared Dispositive Power			
		8.	Snared Dispositive Power			
			6,122,039			
9.	Aggreg	gate 1	Amount Beneficially Owned by Each Reporting Person			
	6,122,039					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares					
11.						
	Telection of older represented by univality in No. (b)					
	6.6%					
12.	Type of Reporting Person (See Instructions)					
	CO					

#### Item 1

- 1(a) Name of Issuer: Myovant Sciences Ltd.
- 1(b) Address of Issuer's Principal Executive Offices:

Suite 1, 3rd Floor 11-12 St. James's Square, London, SW1Y 4LB, United Kingdom

#### Item 2

- 2(a) Name of Person Filing: <u>BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target")</u>
  - 2(b) Address of Principal Business Office or, if none, Residence:
    - BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland
    - Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao
  - 2(c) Citizenship: <u>BB Biotech AG: Switzerland</u>

**Biotech Target N.V.: Curacao** 

- 2(d) Title of Class of Securities Common Shares, \$0.000017727 par value per share
- 2(e) CUSIP Number G637AM102

#### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 6,122,039
- (b) Percent of class: 6.6%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote  $\underline{0}$
- (ii) Shared power to vote or to direct the vote 6,122,039
- (iii) Sole power to dispose or to direct the disposition of  $\underline{0}$
- (iv) Shared power to dispose or to direct the disposition of 6,122,039

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.

#### **Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURES**

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

#### **BB Biotech AG**

Date: February 9, 2022	Ву:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: February 9, 2022	By:	/s/ Ivo Betschart
	·	Signatory Authority
	Name:	Ivo Betschart
	Title:	Signatory Authority
Biotech Target N.V.		
Date: February 9, 2022	By:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: February 9, 2022	Ву:	/s/ Hugo van Neutegem
		Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority

## **Exhibit Index**

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.\*

\* Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on December 28, 2016.